A vaccine for a newly discovered virus that can treat hepatitis C is on track to become available by the end of 2021, according to experts in the field.
Dr Rachael Murphy, a consultant on hepatitis C at Imperial College London and a consultant to the Royal College of Physicians, said it was important that the new vaccine was safe and effective.
The virus is extremely virulent, so it’s very difficult to develop effective drugs, she said.
It has a high virulence and it’s a high-risk disease.
There are a lot of new drugs available that are promising, but the one that’s the most promising is a vaccine.
“It’s a vaccine that is currently on the market that can stop transmission and that’s a lot better than most drugs on the shelf today,” she said, adding that it was possible to have a vaccine on the shelves within a year.
Dr Murphy said there were two types of hepatitis C vaccine: an active vaccine that was approved by the Food and Drug Administration in the US and the inactive vaccine, which was developed by British scientists.
The inactive vaccine is less effective at preventing the virus from attaching to cells, causing the body to reject it and causing more infections.
“The active vaccine can stop that virus from spreading,” she explained.
“So it’s good to see that there’s an active drug available and that the FDA is getting on board with it.”
Dr Murphy is one of a number of experts who have expressed concerns about the new virus.
The vaccine would be the first to be tested on human patients and be able to treat the virus on its own.
“Hepatitis C is the most prevalent cause of liver disease in Europe and in the Americas, and we think there’s a good chance that it will become the most common,” Dr Murphy said.
“We think the vaccine is going to help to stop this outbreak and that it could be the next one.”
But we’ve got to be very cautious.
This vaccine is not perfect, it’s not perfect in every way, but we’re optimistic.
“Dr Michael MacIntyre, professor of medicine at King’s College London, said the vaccine was likely to be approved in 2021.”
We think the active vaccine is a good candidate for approval and it has a good safety profile.””
The FDA is looking at it.
We think the active vaccine is a good candidate for approval and it has a good safety profile.”
And so it has good prospects.
But there’s good news and there’s bad news.
“The active hepatitis C virus, which is not spread through food or water, can cause liver damage and may cause liver cancer.
The United States has been the epicenter of the outbreak and the US government has ordered its healthcare system to ramp up measures to protect against infection.
The WHO estimates that 1.5 million people are infected with the virus each year and more than 200,000 have died.
The US has reported more than 1,500 cases of the virus, with many people infected in the Midwest.
Dr MacIntore said he expected the United States would have to do more to curb the spread of the vaccine in the future, and said that the country needed to be more vigilant about catching the virus.”
That is a very serious matter, and it needs to be looked at, but if you look at how fast we are catching it, we’ve actually got to work more aggressively now than we have in the past,” he said.
Topics:hiv-2081,pandemic-and-acquired-immune-disorder,international-aid-and/or-trade,health,diseases-and,world-politics,united-states,united.european-union,world,united_states_demarcation_region,united._states,aruba,united,unitedstate,colombia,australiaMore stories from Northern Ireland